DAWN / Why Shares of Day One Pharmaceuticals Are Up Monday

Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received more_horizontal

Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The company s more_horizontal

Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigat more_horizontal

Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results.  The Brisbane, Ca more_horizontal

Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-financed, having been VC supported in the initial year more_horizontal

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company d more_horizontal

Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position. more_horizontal

Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Da more_horizontal